FDA-approved GHRH analog with strong evidence for visceral fat reduction.
Tesamorelin is an FDA-approved GHRH analog studied extensively for reduction of visceral adipose tissue (VAT). It has become popular in longevity practice for patients with metabolic-syndrome features.
Nightly subcutaneous injection; effects on visceral fat typically measurable at 12–26 weeks.
GHRH-receptor agonist increasing endogenous GH and IGF-1, with disproportionate lipolytic effect on VAT.
Not indicated in active malignancy. Monitor glucose and IGF-1.
This page is educational and not medical advice. All VitaFlow protocols require evaluation by a licensed Florida physician.
Tesamorelin has strong FDA evidence specifically for visceral fat.
12–26 weeks with lifestyle support.
Only under physician supervision.
IGF-1, fasting glucose, HbA1c.
GHRH analog that stimulates your body's own growth hormone in a physiologic pattern.
Long-acting GHRH analog often paired with Ipamorelin for GH optimization.
Selective GH secretagogue with minimal impact on cortisol, prolactin or appetite.
Miami Beach clinic
1370 Washington Ave, Suite 227, Miami Beach, FL 33139
Hours
Mon–Fri 10am–6pm · Sat–Sun 10am–3pm
Service area
South Florida, including mobile IV therapy where appropriate.
Meet with a VitaFlow physician to design a protocol tailored to your goals, biomarkers, and lifestyle.
